Role of cardiovascular biomarkers for the assessment of mitral stenosis and its complications
详细信息 查看全文
- 作者：Marc Badoza ; 1 ; Mattia Arrigob ; c ; d ; e ; 1 ; Bernard Iungf ; Gullu Amioglug ; Mehmet Birhan Yilmazg ; Nicolas Meneveaua ; Malha Sadouneb ; Agnes Brunettea ; Alexandre Mebazaab ; c ; 2 ; alexandre.mebazaa@aphp.fr" class="auth_mail" title="E-mail the corresponding author ; Marie-France Serondea ; 2
- 关键词：Mitral stenosis ; Pulmonary hypertension ; Biomarker ; BNP ; MR-proANP ; sCD146
- 刊名：European Journal of Internal Medicine
- 出版年：2016
- 出版时间：October 2016
- 年：2016
- 卷：34
- 期：Complete
- 页码：58-62
- 全文大小：300 K
文摘
- •
Plasma BNP, MR-proANP and sCD146 are higher in severe MS compared to moderate MS.
- •
Plasma MR-proANP is not affected by atrial fibrillation in moderate to severe MS.
- •
Pulmonary hypertension secondary to MS is associated with higher BNP and MR-proANP.
- •
MR-proANP may assess severe stenosis and the presence of PH in the early phase.
- •
sCD146 may assess patients with more advanced PH and right ventricular dysfunction.